

Texas Vaccine Providers Webinar Highlights – May 10, 2022

Review the highlights of the topics covered in the May 10th webinar below or view the [full recording](#) for detailed information.

Opening Remarks: Facts of COVID-19 Vaccination

- It is **critical** to increase the COVID-19 vaccination rates for the younger population and ensure there is access for the younger population to receive the vaccines.
 - The most under-immunized group in the United States are individuals under the age of 30.
 - COVID-19 vaccines have been available for 12 to 15-year-olds for a year and only about 55% to 60% are vaccinated.
 - COVID-19 vaccines have been available for 5 to 11-year-olds since the beginning of November 2021 and only 25% to 30% in this age group have been vaccinated.

COVID-19 Vaccine Clinical Guidance

- [The FDA released new guidelines associated with the Janssen \(J&J\) COVID-19 vaccine.](#) Citing the risk of thrombosis with thrombocytopenia syndrome (TTS), the **FDA now limits the use of the J&J vaccine to the following groups:**
 - Individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate.
 - Individuals 18 years of age and older who elect to receive the J&J COVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.
- COVID-19 Vaccine Program providers must have a **digital data logger** with a **valid certificate of calibration** in each storage unit containing the COVID-19 vaccine to ensure vaccines are stored within the correct temperature range.

COVID-19 Vaccine Product Ordering Updates

- As of May 6, 2022**, DSHS revoked ordering privileges for COVID-19 vaccine providers **if they did NOT report their current COVID-19 vaccine inventory by vaccine type to the [Vaccine Allocation Ordering System \(VAOS\)](#) by the 5th of the month.** Providers should access the [Job Aid on Physical Inventory in VAOS](#) for step-by-step guidance on how to report your COVID-19 vaccine inventory.

COVID-19 Vaccine ImmTrac2 Reporting:

- Ensure you are reporting COVID-19 vaccine administered doses into the Texas Immunization Registry, ImmTrac2 using the proper trade names and dose descriptions (full vs. half).
 - Moderna COVID-19 Vaccine Red Cap, Trade Name: **Moderna COVID-19 Vaccine**, can be used for Primary series and Booster doses. Primary series: Full dose (0.5 mL) per dose. Booster dose series: Half dose (0.25 mL) per booster dose
 - Moderna COVID-19 Vaccine Blue Cap, Trade name: **Moderna COVID-19 Booster**, can ONLY be used for Booster doses. It is NOT approved for Primary series use. Booster Dose series: Full Dose (0.5 mL) per booster dose
- Moderna COVID-19 Booster (50mcg/0.5mL) - Blue Cap is in ImmTrac2 **but NOT in circulation yet. Instead use COVID-19 Red Cap (100mcg/0.5mL):**

Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- [EUA Fact Sheet for Janssen Vaccine](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: COVID19VacEnroll@dshs.texas.gov

Live Q&A:

- Below are some of the questions DSHS subject matter experts answered during the webinar's live Q&A sessions.**
- Is giving a dose of 0.5 mL of Moderna COVID-19 Vaccine Red Cap as a booster considered a vaccine administration error?
 - Should the weekly download for the data logger for COVID-19 vaccines be uploaded in to VAOS?
 - Will the Moderna COVID-19 vaccine be available in single dose vials?
 - Do providers have to report "0" for all Moderna, Pfizer adult and pediatric, COVID-19 vaccines? Or just report "0" for just for one?
 - When reporting COVID-19 vaccine inventory for the next month, do providers have to edit the quantity they have on hand?